Table 6.
The FDA-approved antibody fragments
| Generic (brand) name | Format | Target | Indication(s) | Sponsor | Year of FDA approval |
|---|---|---|---|---|---|
| Ranibizumab/Lucentis | Humanized Fab | VEGF | Neovascular (wet) age-related macular degeneration | Gentech | 2006 |
| Abciximab/ReoPro | Chimeric Fab | GPIIb/IIIa | Cardiovascular | Centocor | 1994 |
| Certolizumab pegol/Cimzia | PEGylated humanized Fab’ | TNF-α | Crohn’s disease, rheumatoid arthritis | UCB | 2008 |
| Idarucizumab/Praxbind | Humanized Fab | Dabigatran | Anticoagulation | Boehringer-Ingelheim | 2015 |
| Digibind | Ovine Fab | Digoxin | Digoxin overdose | GlaxoSmithKline | 1986 |
| DigiFab | Ovine Fab | Digoxin | Digoxin overdose | Protherics | 2001 |
| CroFab | Ovine Fab | Crotalidae venom | Pit viper envenomation | Protherics | 2000 |
| Anavip | Equine F(ab’)2 | Crotalidae venom | Pit viper envenomation | Rare Disease Therapeutics | 2015 |
| Anascorp | Equine F(ab’)2 | Centruroides venom | Arizona bark scorpion envenomation | Rare Disease Therapeutics | 2011 |
| Brolucizumab/Beovu | Humanized scFv | VEGF | Neovascular (wet) age-related macular degeneration (AMD) | Novartis | 2019 |
| Caplacizumab/Cablivi | Humanized VHH | vWF | Acquired thrombotic thrombocytopenic purpura (aTTP) | Ablynx | 2019 |